![The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01659-1/MediaObjects/41591_2021_1659_Fig1_HTML.png)
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine
![Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/546_706079_1/Slide4.jpg)
Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD
![Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ](https://www.hkmj.org/system/files/hkmj197802-table.jpg)
Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus | HKMJ
![Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics](https://pub.mdpi-res.com/cells/cells-11-03372/article_deploy/html/images/cells-11-03372-ag-550.jpg?1667973845)
Cells | Free Full-Text | Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics
![Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00485/article_deploy/html/images/pharmaceutics-13-00485-g001-550.jpg)
Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
![Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial - Laffel - 2018 - Diabetic Medicine - Wiley Online Library Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial - Laffel - 2018 - Diabetic Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f66554fd-6d5f-4df8-a88b-235e49e0bfbb/dme13629-fig-0001-m.jpg)